Latest Breaking News On - Jarl ulf jungnelius - Page 1 : comparemela.com

Beactica Therapeutics appoints Jarl Ulf Jungnelius M D to its Board of Directors as it advances towards clinical-stage activities

/PRNewswire/ Beactica Therapeutics AB, the Swedish precision oncology company, today announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of.

Healthcom gmbUlf jungneliusEli lilly companyClinical researchBiovica internationalKarolinska instituteVice presidentEli lillySenior oncology advisorRyvu therapeuticsJarl ulf jungneliusBeactica therapeuticsBeactica therapeutics ab

CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vastra gotalands lanUlf jungneliusMerck cieNasdaq stockholmChief executive officerIsofol medicalIsofol boardJarl ulf jungnelius

Final data from the AGENT study confirms topline results

Final data from the AGENT study confirms topline results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vastra gotalands lanUlf jungneliusMerck cieNasdaq stockholmJarl ulf jungneliusChief executive officere mailChief medical officere mail

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

STOCKHOLM, June 28, 2022 /PRNewswire/ The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Tuesday, 28 June 2022. At the Annual General Meeting, the following principal

Ulf jungneliusJennifer jacksonOncopeptides pepaxtiCecilia daun wennborgAnna svanbergRolf gulliksenBrian stuglikGlobal head of corporate communicationsAnnual general meetingJarl ulf jungneliusPer samuelssonNomination committeesNasdaq stockholmShare awardsGrant dateGlobal head

Annual General Meeting in Oncopeptides AB (publ)

/PRNewswire/ The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, ("Oncopeptides" or.

United statesStiftelsen industrifondenJennifer jacksonMonte carloUlf jungneliusCecilia daun wennborgBrian stuglikStaffan lindstrandAnna svanbergRolf gulliksenAdvokatfirman vingeCaroline murrayJohan winnerbladObjectthe companyArticles of associationSwedish companies registration office sw